Navigation Links
Scripps Research compound blocks brain cell destruction in Parkinson's disease
Date:2/11/2011

JUPITER, FL, February 11, 2011 Scientists from the Florida campus of The Scripps Research Institute have produced the first known compound to show significant effectiveness in protecting brain cells directly affected by Parkinson's disease, a progressive and fatal neurodegenerative disorder.

Although the findings were in animal models of the disease, the effectiveness of the compound, combined with its potential to be taken orally, offers the tantalizing possibility of a potentially useful future therapy for Parkinson's disease patients. The results were published in two separate studies in the journal ACS Chemical Neuroscience.

"These studies present compelling data on the first oral, brain-penetrating inhibitor to show significant efficacy in preventing neurodegeneration in both mouse and rat models of Parkinson's disease," said team leader Philip LoGrasso, a professor in the Department of Molecular Therapeutics and senior director for drug discovery at Scripps Florida. "The compound offers one of the best opportunities we have for the development of an effective neuroprotective treatment."

The new small moleculelabeled SR-3306is aimed at inhibiting a class of enzymes called c-jun-N-terminal kinases (JNK). Pronounced "junk," these enzymes have been shown to play an important role in neuron (nerve cell) survival. As such, they have become a highly viable target for drugs to treat neurodegenerative disorders such as Parkinson's disease.

"A drug like SR-3306 that prevents neurodegeneration would be a quantum leap in the clinical treatment of Parkinson's because all current therapies treat only the symptoms of the disease, not the underlying pathologies," LoGrasso said.

Patients with Parkinson's disease suffer from the loss of a group of neurons in the substantia nigra pars compacta (SNpc), part of the midbrain involved in motor control. These cells produce dopamine, a neurotransmitter that plays a key role in motor reflexes and cognition. The disease also affects projecting nerve fibers in the striatum, a part of the forebrain filled with cells that interact with dopamine. Stopping the Progression of Neuron Destruction in Animal Models

The SR-3306 compound, which has been in development at Scripps Florida for several years, performed well in both cell culture and animal models. In cell culture, the compound showed greater than 90 percent protection against induced cell death of primary dopaminergic neurons, while in mouse models of induced neuron death, the compound showed protective levels of approximately 72 percent.

The scientists went one step further, testing the new compound in a rat model, which duplicates the physical symptoms often seen with the human diseasea pronounced and progressive loss of motor skills. The results showed SR-3306 provided a protection level of approximately 30 percent in the brain, a level that reduced the dysfunctional motor responses by nearly 90 percent.

"It was a surprise that level of neuroprotection reduced the behavioral impact so strongly," LoGrasso said, "but it's indicative of how it might perform in human patients. While SR-3306 doesn't represent a cure, it does appear to have the potential of stopping the progression of the disease."

The new studies are part of a $7.6 million multiyear grant awarded to LoGrasso in 2008 by the National Institutes of Neurological Disorders and Stroke (NINDS). The grant will enable Scripps Research and potential partners to file an application for an investigational new drug (IND)the first step in the lengthy clinical trials process required by the U.S. Food and Drug Administration before a new drug can be brought to market.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related medicine news :

1. Scripps Health Begins Pioneering Study of Human Tumor Sequencing in Cancer Patients
2. Top Scientists Explore the Origin of Life in Annual Lasker Lecture at Scripps Research Institute Florida Campus
3. Scripps Blood & Marrow Transplant Program Celebrates 30th Anniversary of Providing Life-Saving Care
4. Scripps Memorial Hospital La Jolla First in San Diego to Achieve Magnet Nursing Re-designation
5. Scripps Announces Plans for Region's First Proton Therapy Center; $185 Million Facility to Offer Advanced Care to Cancer Patients
6. Scripps Research scientists share $2 million in Florida state research grants
7. Scripps Center for Executive Health Now Offers Genetic Testing
8. Scripps Research scientists uncover previously unknown natural mechanism that controls cocaine use
9. NIH awards Scripps Florida scientists $2.3 Million to develop drug addiction treatments
10. Scripps Research scientists solve long-standing mystery of protein quality control mechanism
11. Scripps and Trius team up to develop new antibiotics with US Department of Defense grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... After years ... General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief ... Hospital. He successfully completed his first three-year term as chief and began a second ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: ... wait longer to access the treadmills. It’s a predictable trend. After the excesses of ... and get in shape by joining gyms, starting new walking or running routines, or ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. Lydia ... No Cost Dental Day to individuals in need. The event is scheduled to take ... Cost Dental Day is to provide dental care to community members in need. Each ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
(Date:2/5/2016)... ... ... –This week, Atascadero water heater company First Call Plumbing has issued ... report, click here or see below. , There are two main ... the type chosen is almost entirely up to personal preference. However, tankless water heaters ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)...  Despite the recent explosion in Big Data, the ... embrace Big Data due to the inherent costs and ... organizations have begun looking to Big Data as a ... --> --> According ... Big Data has started informing many decisions. In fact, ...
(Date:2/5/2016)... Amgen (NASDAQ: AMGN ) will present at ... at 9:15 a.m. ET on Wednesday, Feb. 10, 2016, in ... Meline , executive vice president and chief financial officer at ... presentation can be accessed from the Events Calendar on Amgen,s ... webcast will also be available on Amgen,s website for at ...
(Date:2/5/2016)... -- Redwood Scientific Technologies, Inc. announced today the development and ... balance their hormones. This product will be featuring Redwood,s ... Cardiff , President and CEO. "I am proud that ... of women across the country and around the world ... research and development team is confident that through the ...
Breaking Medicine Technology: